Susan J Ramus

List of Publications by Year in Descending Order

228 papers	13,033 citations	60 h-index	106 g-index
244 ext. papers	15,342 ext. citations	8.1 avg, IF	4.8 L-index

#	Paper	IF	Citations
228	Cancer Risks Associated With and Pathogenic Variants.. *Journal of Clinical Oncology*, **2022**, JCO2102112	2.2	7
227	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
226	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
225	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. *Journal of Medical Genetics*, **2021**,	5.8	5
224	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
223	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. *British Journal of Cancer*, **2021**, 125, 265-276	8.7	1
222	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	0.8	3
221	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
220	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. *Journal of the National Cancer Institute*, **2021**, 113, 301-308	9.7	3
219	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
218	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
217	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
216	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
215	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
214	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51
213	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
212	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133

211	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
210	Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. *Cancers*, **2020**, 12,	6.6	5
209	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. *European Journal of Epidemiology*, **2020**, 35, 1025-1042	12.1	2
208	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
207	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
206	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
205	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. *Clinical Cancer Research*, **2019**, 25, 5937-5946	12.9	21
204	Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews Cancer*, **2019**, 19, 339-348	31.3	17
203	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
202	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
201	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
200	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. *Cancer Research*, **2019**, 79, 467-481	10.1	11
199	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
198	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
197	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
196	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
195	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. *Journal of the National Cancer Institute*, **2018**, 110, 714-725	9.7	92
194	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2018**, 47, 450-459	7.8	8

193	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *American Journal of Epidemiology*, **2018**, 187, 366-377	3.8	7
192	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 395-404	4	25
191	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. *Gynecologic Oncology*, **2018**, 150, 527-533	4.9	9
190	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
189	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
188	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
187	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
186	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *Journal of Medical Genetics*, **2018**, 55, 546-554	5.8	30
185	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
184	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18
183	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
182	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2017**, 116, 1223-1228	8.7	11
181	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 116-125	4	5
180	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
179	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
178	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 420-424	4	3
177	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. *Clinical Cancer Research*, **2017**, 23, 1552-1563	12.9	49
176	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153

175	Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. *Oncotarget*, **2017**, 8, 50930-50940	3.3	30
174	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
173	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. *International Journal of Cancer*, **2016**, 139, 2646-2654	7.5	6
172	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
171	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
170	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
169	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8
168	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. *International Journal of Gynecological Pathology*, **2016**, 35, 430-41	3.2	121
167	PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	34
166	Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer. *Oncology*, **2016**, 90, 59-68	3.6	7
165	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiology*, **2016**, 41, 71-9	2.8	17
164	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
163	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
162	Evidence of a genetic link between endometriosis and ovarian cancer. *Fertility and Sterility*, **2016**, 105, 35-43.e1-10	4.8	26
161	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. *PLoS ONE*, **2016**, 11, e0153844	3.7	12
160	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
159	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
158	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7

157	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
156	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstetrics and Gynecology*, **2016**, 127, 828-836	4.9	24
155	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Human Molecular Genetics*, **2016**, 25, 3600-3612	5.6	9
154	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
153	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
152	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
151	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 1619-1630	7.8	77
150	Telomere structure and maintenance gene variants and risk of five cancer types. *International Journal of Cancer*, **2016**, 139, 2655-2670	7.5	30
149	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
148	Genome-wide significant risk associations for mucinous ovarian carcinoma. *Nature Genetics*, **2015**, 47, 888-97	36.3	60
147	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
146	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
145	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
144	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. *Molecular Cancer Therapeutics*, **2015**, 14, 1495-503	6.1	13
143	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
142	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
141	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48
140	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. *Journal of Clinical Oncology*, **2015**, 33, 2901-7	2.2	200

139	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	239
138	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18
137	Efficient molecular subtype classification of high-grade serous ovarian cancer. *Journal of Pathology*, **2015**, 236, 272-7	9.4	63
136	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
135	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
134	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
133	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
132	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
131	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Human Genetics*, **2014**, 133, 481-97	6.3	21
130	The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Human Molecular Genetics*, **2014**, 23, 4703-9	5.6	90
129	Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *Journal of the National Cancer Institute*, **2014**, 106, djt431	9.7	149
128	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *Molecular Nutrition and Food Research*, **2014**, 58, 2023-35	5.9	8
127	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *British Journal of Cancer*, **2014**, 111, 2297-307	8.7	49
126	Variation in NF-B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1421-7	4	11
125	Risk of ovarian cancer and the NF-B pathway: genetic association with IL1A and TNFSF10. *Cancer Research*, **2014**, 74, 852-61	10.1	36
124	Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunology Research*, **2014**, 2, 332-40	12.5	20
123	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
122	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*, **2013**, 15, 402	8.3	30

121	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
120	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
119	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
118	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes and Control*, **2013**, 24, 989-1004	2.8	69
117	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. *Lancet Oncology, The*, **2013**, 14, 1226-32	21.7	73
116	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
115	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1677-86	4	53
114	Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 880-90	4	37
113	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*, **2013**, 20, 251-62	5.7	135
112	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
111	Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 987-92	4	20
110	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
109	Inherited variants in regulatory T cell genes and outcome of ovarian cancer. *PLoS ONE*, **2013**, 8, e53903	3.7	19
108	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
107	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA - Journal of the American Medical Association*, **2012**, 307, 382-90	27.4	427
106	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncology, The*, **2012**, 13, 385-94	21.7	612
105	ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2012**, 23, 1805-10	2.8	27
104	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20

103	Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 529-36	4	7
102	Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1156-66	4	92
101	Ovarian cancer risk associated with inherited inflammation-related variants. *Cancer Research*, **2012**, 72, 1064-9	10.1	35
100	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
99	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
98	Genome-wide association study for ovarian cancer susceptibility using pooled DNA. *Twin Research and Human Genetics*, **2012**, 15, 615-623	2.2	8
97	Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers. *Pathology*, **2012**, 44, 89-98	1.6	6
96	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. *Fertility and Sterility*, **2011**, 95, 40-5	4.8	18
95	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. *Journal of Clinical Epidemiology*, **2011**, 64, 525-30	5.7	27
94	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. *Breast Cancer Research*, **2011**, 13, R14	8.3	9
93	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
92	Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. *PLoS ONE*, **2011**, 6, e24987	3.7	41
91	Morphological predictors of BRCA1 germline mutations in young women with breast cancer. *British Journal of Cancer*, **2011**, 104, 903-9	8.7	35
90	A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. *BMC Cancer*, **2011**, 11, 119	4.8	16
89	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. *International Journal of Cancer*, **2011**, 128, 936-43	7.5	44
88	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. *International Journal of Cancer*, **2011**, 128, 2063-74	7.5	49
87	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. *Human Molecular Genetics*, **2011**, 20, 2263-72	5.6	18
86	Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1028-31	4	

85	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
84	LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Research*, **2011**, 71, 3896-903	10.1	70
83	MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1793-7	4	18
82	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
81	Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e19642	3.7	4
80	Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. *PLoS ONE*, **2011**, 6, e20703	3.7	20
79	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
78	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nature Genetics*, **2010**, 42, 874-9	36.3	277
77	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
76	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
75	Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 600-4	4	20
74	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1822-30	4	22
73	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
72	Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genetics*, **2010**, 6, e1001016	6	42
71	ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 245-50	4	64
70	Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. *Neoplasia*, **2010**, 12, 579-89	6.4	32
69	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. *Genome Research*, **2010**, 20, 440-6	9.7	638
68	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. *Gynecologic Oncology*, **2010**, 119, 479-83	4.9	25

67	A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. *International Journal of Molecular Epidemiology and Genetics*, **2010**, 1, 272-7	0.9	7
66	Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 935-44	4	31
65	Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. *British Journal of Cancer*, **2009**, 101, 1461-8	8.7	34
64	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. *Human Molecular Genetics*, **2009**, 18, 2297-304	5.6	37
63	Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2123-31	4	13
62	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. *Human Molecular Genetics*, **2009**, 18, 1869-78	5.6	16
61	Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2009**, 69, 2349-57	10.1	52
60	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. *International Journal of Cancer*, **2009**, 124, 1037-44	7.5	10
59	The clonal evolution of metastases from primary serous epithelial ovarian cancers. *International Journal of Cancer*, **2009**, 124, 1579-86	7.5	53
58	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nature Genetics*, **2009**, 41, 996-1000	36.3	240
57	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2009**, 100, 412-20	8.7	42
56	Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. *British Journal of Cancer*, **2009**, 100, 993-1001	8.7	21
55	Risk of ovarian cancer in women with first-degree relatives with cancer. *Acta Obstetricia Et Gynecologica Scandinavica*, **2009**, 88, 449-56	3.8	13
54	Role of genetic polymorphisms and ovarian cancer susceptibility. *Molecular Oncology*, **2009**, 3, 171-81	7.9	59
53	The contribution of BRCA1 and BRCA2 to ovarian cancer. *Molecular Oncology*, **2009**, 3, 138-50	7.9	125
52	Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study. *Breast Cancer Research*, **2009**, 11, R80	8.3	70
51	Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. *PLoS ONE*, **2009**, 4, e5983	3.7	33
50	An epigenetic signature in peripheral blood predicts active ovarian cancer. *PLoS ONE*, **2009**, 4, e8274	3.7	245

49	Somatic Genetic Development in Epithelial Ovarian Cancer **2009**, 215-246		1
48	Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. *British Journal of Cancer*, **2008**, 98, 282-8	8.7	42
47	Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. *European Journal of Cancer*, **2008**, 44, 2259-65	7.5	20
46	Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. *Clinical Cancer Research*, **2008**, 14, 5840-8	12.9	33
45	Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 1090-5	12.9	24
44	The effects of common genetic variants in oncogenes on ovarian cancer survival. *Clinical Cancer Research*, **2008**, 14, 5833-9	12.9	30
43	BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. *Clinical Cancer Research*, **2008**, 14, 3761-7	12.9	77
42	Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. *Cancer Research*, **2008**, 68, 8837-42	10.1	10
41	Multiple loci with different cancer specificities within the 8q24 gene desert. *Journal of the National Cancer Institute*, **2008**, 100, 962-6	9.7	283
40	Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 3567-72	4	14
39	Consortium analysis of 7 candidate SNPs for ovarian cancer. *International Journal of Cancer*, **2008**, 123, 380-388	7.5	66
38	Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. *PLoS ONE*, **2007**, 2, e268	3.7	47
37	Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. *Human Mutation*, **2007**, 28, 1207-15	4.7	67
36	Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online. *Human Mutation*, **2007**, 28, 525-6	4.7	8
35	Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. *Journal of Pathology*, **2007**, 211, 286-95	9.4	94
34	Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 2557-65	4	58
33	Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2007**, 67, 3027-35	10.1	75
32	BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study. *European Journal of Cancer*, **2007**, 43, 823-7	7.5	18

31	Common variants in RB1 gene and risk of invasive ovarian cancer. *Cancer Research*, **2006**, 66, 10220-6	10.1	34
30	Common variants in mismatch repair genes and risk of invasive ovarian cancer. *Carcinogenesis*, **2006**, 27, 2235-42	4.6	64
29	Phenotype-directed analysis of genotype in early-onset, familial breast cancers. *Pathology*, **2006**, 38, 520-7	1.6	7
28	Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. *Cancer Genetics and Cytogenetics*, **2005**, 160, 134-40		33
27	Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. *British Journal of Cancer*, **2004**, 91, 1911-5	8.7	119
26	Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. *Oncogene*, **2004**, 23, 5697-702	9.2	92
25	Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. *Clinical and Experimental Metastasis*, **2004**, 21, 543-52	4.7	68
24	LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. *Clinical and Experimental Metastasis*, **2004**, 21, 535-41	4.7	14
23	Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. *International Journal of Gynecological Pathology*, **2004**, 23, 29-34	3.2	68
22	BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. *Cancer Research*, **2003**, 63, 417-23	10.1	30
21	Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. *European Journal of Surgical Oncology*, **2001**, 27, 278-81	3.6	33
20	Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. *International Journal of Gynecological Pathology*, **2000**, 19, 390-4	3.2	14
19	Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. *International Journal of Cancer*, **2000**, 87, 317-21	7.5	77
18	Idiopathic slow-transit constipation is not associated with mutations of the RET proto-oncogene or GDNF. *Diseases of the Colon and Rectum*, **2000**, 43, 851-7	3.1	12
17	Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. *Human Pathology*, **2000**, 31, 1420-1424	3.7	71
16	Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. *Genes Chromosomes and Cancer*, **1999**, 25, 91-6	5	64
15	Genotype and intellectual phenotype in untreated phenylketonuria patients. *Pediatric Research*, **1999**, 45, 474-81	3.2	15
14	Single-tube chemical cleavage of mismatch: successive treatment with hydroxylamine and osmium tetroxide. *BioTechniques*, **1996**, 21, 216-8, 220	2.5	6

13	Polymorphism in the 3Ountranslated region of the phenylalanine hydroxylase gene detected by enzyme mismatch cleavage: evolution of haplotypes. *Human Genetics*, **1995**, 96, 741-3	6.3	
12	Mutations Ivs4nt1, 47delCT, and G148S identified in the phenylalanine hydroxylase gene by RT-PCR of illegitimate transcripts and chemical cleavage of mismatch. *Human Mutation*, **1995**, 6, 250-1	4.7	2
11	CpG hotspot causes second mutation in codon 408 of the phenylalanine hydroxylase gene. *Human Genetics*, **1992**, 90, 147-8	6.3	3
10	Complete mutation detection using unlabeled chemical cleavage. *Human Mutation*, **1992**, 1, 63-9	4.7	32
9	Illegitimate transcription of phenylalanine hydroxylase for detection of mutations in patients with phenylketonuria. *Human Mutation*, **1992**, 1, 154-8	4.7	16
8	A spontaneous mutation causing unstable Hb Hammersmith: detection of the beta 42 TTT----TCT change by CCM and direct sequencing. *British Journal of Haematology*, **1991**, 79, 127-9	4.5	9
7	Simultaneous screening for beta-thalassemia mutations by chemical cleavage of mismatch. *Genomics*, **1991**, 11, 48-53	4.3	26
6	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
5	A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors		2
4	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2
3	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2
2	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
1	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma		1